Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Seven brokers give Plus Therapeutics an average rating of "Moderate Buy" (1 sell, 1 hold, 4 buy, 1 strong buy) with a mean 1‑year price target of $7.25.
• Financial snapshot: Shares trade around $0.57 with a $78.1M market cap, the company is unprofitable (recent quarterly EPS -$0.04 missed estimates) and has a wide 52‑week range of $0.16–$2.31.
• Clinical pipeline: Plus is a clinical‑stage radiotherapeutics developer, with lead candidate 90Y‑HP‑DO3A in Phase 2 for recurrent high‑grade gliomas driving investor interest.

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $7.25.

PSTV has been the subject of a number of recent analyst reports. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $21.00 to $19.00 and set a "buy" rating for the company in a research note on Friday, November 21st. D Boral Capital upgraded shares of Plus Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 3rd. Zacks Research lowered shares of Plus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 11th. D. Boral Capital reissued a "buy" rating and issued a $5.00 price target on shares of Plus Therapeutics in a report on Thursday, December 11th. Finally, HC Wainwright restated a "buy" rating and issued a $2.00 price objective on shares of Plus Therapeutics in a research report on Wednesday, November 26th.

Plus Therapeutics Stock Performance

PSTV opened at $0.57 on Friday. The company has a fifty day moving average price of $0.59 and a two-hundred day moving average price of $0.51. The firm has a market capitalization of $78.13 million, a PE ratio of -0.30 and a beta of 0.82. Plus Therapeutics has a 52 week low of $0.16 and a 52 week high of $2.31.

Plus Therapeutics (NASDAQ:PSTV - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.50 million. Equities analysts forecast that Plus Therapeutics will post -2.3 EPS for the current year.

Hedge Funds Weigh In On Plus Therapeutics

Institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in Plus Therapeutics during the 2nd quarter worth approximately $41,000. Susquehanna International Group LLP acquired a new position in shares of Plus Therapeutics in the third quarter valued at approximately $46,000. Scientech Research LLC bought a new stake in shares of Plus Therapeutics during the third quarter worth $100,000. Finally, Altium Capital Management LLC bought a new stake in shares of Plus Therapeutics during the third quarter worth $628,000. Institutional investors own 3.28% of the company's stock.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company's lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.